Reshaping the Treatment Landscape for Recurrent/Metastatic Nasopharyngeal Carcinoma
May 26th 2022In the context of checkpoint blockade in nasopharyngeal carcinoma, the results of the phase 3 RATIONALE-309 trial support earlier findings of the role immunotherapy may play for patients in the first line.
Combinations Gain Momentum as First-Line Treatments for Unresectable Hepatocellular Carcinoma
May 25th 2022A panel of hepatobiliary tumor experts discuss several pivotal phase 3 clinical trials examining combination approaches that have expanded or are anticipated to expand the treatment armamentarium for treatment-naïve patients with unresectable hepatocellular carcinoma.
The Saga of Regional Therapy in the Treatment of Ovarian Cancer
May 17th 2022Despite numerous well-designed and conducted randomized trials, a definitive answer to the role of specific disease management remains unclear, particularly in the discussions of the optimal role for the regional delivery of cytotoxic chemotherapy in the treatment of patients with ovarian cancer.